Why Is Vyvanse So Expensive? 2026 Cost Reports
HealthRX.com
Insurance rules, not approval dates, drive what you pay
Key numbers
- 70 mgHighest Vyvanse capsule strength, listed under Takeda's brand applicationSource: accessdata.fda.gov, as cited Nov 7, 2026
- 10 to 60 mgChewable tablet strength range of Vyvanse, approved separately from the capsulesSource: accessdata.fda.gov, as cited Nov 7, 2026
- 10 mg/mLConcentration of Arynta, a lisdexamfetamine oral solution approved separately from generic capsulesSource: accessdata.fda.gov, as cited Nov 7, 2026
See the public record for Lisdexamfetamine
At a glance
- Brand application / Vyvanse, Takeda, NDA 021977, approved 23 Feb 2007 [1]
- Chewable tablets / Separate application NDA 208510, approved 28 Jan 2017 [3]
- Generic capsules and chewable tablets / First approved 25 Aug 2023; more approved since [1][2]
- Oral solution / Arynta 10 mg/mL, Azurity, approved 16 Jun 2025 [2]
- Controlled status / Prescription only, Schedule II [4]
- Approved uses / ADHD in adults and children 6 and older; moderate to severe binge eating disorder in adults [4]
What FDA records show about Vyvanse
Vyvanse capsules in 10, 20, 30, 40, 50, 60 and 70 mg are listed under Takeda's new drug application NDA 021977, originally approved on 23 February 2007 [1]. The chewable tablets, 10 to 60 mg, were approved under a separate application, NDA 208510, on 28 January 2017 [3]. Both are prescription-only and Schedule II [4]. The label in effect is dated 30 April 2026 [4].
The label covers two uses: ADHD in adults and pediatric patients 6 years and older, and moderate to severe binge eating disorder in adults. It states that Vyvanse is not indicated for weight loss and that its safety and effectiveness for obesity have not been established [4].
Generic lisdexamfetamine since 2023
Generic lisdexamfetamine capsules and chewable tablets were first approved on 25 August 2023 under many abbreviated new drug applications, including those held by Actavis, Hikma, Amneal, Mylan, Sun, Norwich, Rhodes, Teva and Ascent. Later approvals include Sandoz on 26 July 2024 and Granules on 29 January 2025 [1][2]. These are FDA approval dates, not launch dates.
FDA separately approved Arynta, a 10 mg/mL lisdexamfetamine oral solution from Azurity, on 16 June 2025 under its own application, NDA 219847 [2]. It is not a generic capsule or chewable tablet.
Capsules and chewable tablets
The label states that capsules and chewable tablets can be substituted for each other milligram for milligram [4], so a 30 mg prescription is a 30 mg dose in either form.
What this means for a bill
FDA approval records alone cannot explain why a particular Vyvanse prescription was expensive. They show a brand product approved in 2007, a chewable form added in 2017, generic capsules and chewable tablets approved from August 2023, and a liquid approved in 2025 [1][3][2]. They do not show launch timing, pharmacy availability, or the amount charged, and approval of a generic does not prove one was available for a specific prescription.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
What people on Reddit report
Reddit users whose plans did not cover brand Vyvanse, or who were told to try other drugs or get a tiering exception first. Some were on state health plans.
Step therapy is where you have to prove that less expensive drugs have not been effective. Some plans require that you try at least two other lower tier drugs first.Read the source discussion
It may be a matter of step therapy being required (basically means you need to try and fail other drugs first). It's also possible that Vyvanse is classified as a formulary exception. We'd need to review the formulary to help make that determination, but you can certainly do that on your own if you have access to your insurance portal.Read the source discussion
It may be that they will only cover the generic. Brand name Vyvanse is expensive. Did you speak with an insurance representative?Read the source discussion
If you can use the non-generic form of Vyvanse, you might be able to qualify for copay support from the manufacturer if you have a low household income.Read the source discussion
Check if your plan allows a tiering exception and have your prescriber submit for one indicating which tier 1 meds you've already tried and therefore this one is medically appropriate or necessary and as such should be reduced to tier 1.Read the source discussion
Questions worth asking
What pharmacies paid for Vyvanse, 2013 to 2026
The rate on file went from $5.99 in Nov 2013 to $12.35 in Nov 2026, up 106%.
- Vyvanse 30 mg capsule: $12.35 per capsule in Nov 2026
NADAC is the average price retail pharmacies told a CMS survey they paid wholesalers. For Vyvanse the latest file puts that at $12.35 per capsule. It is close to a list price: it leaves out the rebates the maker later pays insurers and Medicaid, and it is not what a patient is charged.
| First rate on file | $5.99 in Nov 2013 |
|---|---|
| Latest rate | $12.35 in Nov 2026 |
| Change, first to latest | up 106% |
| Highest rate | $12.40 in Aug 2024 |
| Biggest one-week move | up 9%, file dated Jan 13, 2016 (from $7.37 to $8.03) |
Every value in the chart (53 dates)
| Month | Vyvanse 30 mg capsule |
|---|---|
| $5.99 | |
| $6.53 | |
| $6.50 | |
| $6.50 | |
| $6.50 | |
| $7.04 | |
| $7.02 | |
| $7.37 | |
| $7.37 | |
| $8.02 | |
| $8.02 | |
| $8.02 | |
| $8.00 | |
| $8.67 | |
| $8.67 | |
| $8.67 | |
| $8.66 | |
| $9.44 | |
| $9.44 | |
| $9.44 | |
| $9.44 | |
| $9.44 | |
| $9.72 | |
| $9.72 | |
| $9.72 | |
| $10.21 | |
| $10.20 | |
| $10.20 | |
| $10.19 | |
| $10.70 | |
| $10.70 | |
| $10.70 | |
| $10.71 | |
| $11.25 | |
| $11.25 | |
| $11.25 | |
| $11.25 | |
| $11.81 | |
| $11.81 | |
| $11.81 | |
| $11.80 | |
| $12.39 | |
| $12.39 | |
| $12.40 | |
| $12.39 | |
| $12.39 | |
| $12.38 | |
| $12.37 | |
| $12.36 | |
| $12.35 | |
| $12.35 | |
| $12.35 | |
| $12.35 |
Read from every weekly NADAC file from Nov 28, 2013 to Nov 11, 2026 (677 files carry a rate here). Package codes were tied to Vyvanse through RxNorm. Each point is the middle rate across those codes in the last file of the quarter.
6 other strengths or pack sizes are on file at the same rate as a line shown and are not drawn separately. 6 products left out: filed in a different unit.
Frequently asked questions
Is there a generic version of Vyvanse?
What forms does Vyvanse come in?
What is Arynta?
What is Vyvanse approved to treat?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is there a way to get Vyvanse cheaper?
FDA records do not show a way to lower the cost. FDA first approved generic lisdexamfetamine capsules and chewable tablets on 25 August 2023, with more approved since, but those are approval dates, not launch dates, and they do not show whether a given pharmacy stocked the product.
What's the deal with generic Vyvanse still so expensive?
Approval records do not give generic prices. FDA first approved generic lisdexamfetamine capsules and chewable tablets on 25 August 2023, but approval dates are not launch dates, and approval does not prove a generic was available for a specific prescription.
Why is Vyvanse so expensive even with my insurance?
FDA records cannot explain why a particular Vyvanse prescription costs what it does, because they list approved products and dates rather than pharmacy prices. They do not show the amount charged, pharmacy availability, or launch timing.
References
Show all 6 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- Drugs@FDA: FDA-Approved Drugs.
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, Takeda prescribing information. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, Takeda label
- Reddit participants. Insurance doesn't cover Vyvanse (r/HealthInsurance). Accessed 2026-11-11.
- Reddit participants. [deleted by user] (r/HealthInsurance). Accessed 2026-11-11.